Association of anticardiolipin antibodies with vascular access occlusion in hemodialysis patients: Cause or effect?

Nephron

Volumn 86, Issue 4, 2000, Pages 447-454

  Haviv, Yosef S ^a,b  

^a HADASSAH HEBREW UNIVERSITY MEDICAL CENTER   (Israel)

^b University of Alabama at Birmingham   (United States)

Author keywords

Anticardiolipin antibody; Antiphospholipid antibody; Arteriovenous access; Hemodialysis; Vascular occlusion

Indexed keywords

BETA2 GLYCOPROTEIN 1 ANTIBODY; CARDIOLIPIN ANTIBODY; IMMUNOGLOBULIN G; IMMUNOGLOBULIN M; PROTEIN ANTIBODY; UNCLASSIFIED DRUG;

ADULT; AGED; ANTIBODY BLOOD LEVEL; ARTICLE; BLOOD VESSEL OCCLUSION; CHRONIC KIDNEY FAILURE; CONTROLLED STUDY; DISEASE ASSOCIATION; FEMALE; HEMODIALYSIS; HEMODIALYSIS PATIENT; HUMAN; INCIDENCE; MAJOR CLINICAL STUDY; MALE; PREDICTION; PRIORITY JOURNAL; UREMIA; VASCULAR ACCESS;

AGED; ANTIBODIES; CARDIOLIPINS; CATHETERS, INDWELLING; ENZYME-LINKED IMMUNOSORBENT ASSAY; FEMALE; HUMANS; IMMUNOGLOBULIN A; MALE; MIDDLE AGED; RENAL DIALYSIS; UREMIA;

EID: 0034531145     PISSN: 00282766     EISSN: None     Source Type: Journal    
DOI: 10.1159/000045833     Document Type: Article

References (48)

1. A hemorrhagic disorder caused by circulating anticoagulants in patients with disseminated lupus erythemato-sus
2. Thrombosis in systemic lupus erythemato-sus despite circulating anticoagulants
3. Is the antiphospholipid syndrome caused by antibodies directed against physiologically relevant phospholipid-protein complexes?
4. A phospholipid-beta-2-glyco-protein I complex is an antigen for anticardiolipin antibodies occcuring in autoimmune disease but not with infection
5. Immunization with anticardiolipin cofactor (beta-2-glycoprotein I) induces experimental antiphospholipid syndrome in naive mice
6. Role of phosphatidyletha-nolamine in inhibition of activated protein C activity by antiphospholipid antibodies
7. Acquired activated protein C resistance caused by factor Va antibody: A possible mechanism of increased thrombosis in the antiphospholipid antibody syndrome
8. Antiphos-pholipid antibodies directed against a combination of phospholipids with prothrombin, protein C or protein S: An explanation for their pathogenic mechanism?
9. Characteristics of the clinical findings in patients with idiopathic thrombocytopenic purpura who are positive for antiphospholipid antibodies
10. Guidelines for testing and revised criteria for lupus anticoagulants
11. Chronic relapsing thrombotic thrombocytopenic purpura and antiphospholipid antibodies
12. Antibodies against phospholipids other than cardiolipin: Potential roles for both phospholipid and protein
13. Binding of anticardiolipin antibodies to protein C via β2-glycoprotein-1: A possible mechanism in the inhibitory effect of antiphos-pholipid antibodies on the protein C system
14. Autoantibodies to phospholipid-binding plasma proteins: A new view of lupus anticoagulants and other antiphospholipid antibodies
15. Identification of beta-2-glycoprotein-1 critical for lipid binding and anticardiolipin cofactor activity
16. Induction of antiphospholipid autoanti-bodies by immunization with beta-2-glycoprotein-1
17. Heterogeneity of anticardiolipin antibodies defined by the cardiolipin factor
18. Coagulation assays for the lupus anticoagulant: Review and critique of the current methodology
19. A prospective epidemiological study on the occurrence of antiphospholipid antibody: The Montpellier Antiphospholipid (MAP) Study
20. A prospective evaluation of atherosclerosis risk factors and hypercoagulability in young adults with premature atherosclerosis
21. Antiphos-pholipid antibodies in vascular surgery patients. A cross-sectional study
22. Raised concentrations of antibodies to cardiolipin in patients receiving dialysis
23. Association between anticardiolipin antibody and frequent clotting problems in hemodialysis
24. Anticardiolipin antibodies and lupus anticoagulant in end-stage renal disease
25. Anticardiolipin antibodies in long-term dialysis patients
26. Anticardiolipin antibodies in patients on regular hemodialysis: An epiphenomenon?
27. Neuropathologic findings in multi-infarct dementia associated with anticar-diolipin antibody. Evidence for endothelial injury as the primary event
28. Activation of endothelial cells in thrombosis and vasculitis
29. Endothelial cells as a target for anti-phospholipid antibodies: Role of anti-β2-glyco-protein I antibodies
30. Cross-reaction between antibodies to oxidized LDL and to cardiolipin in systemic lupus erythematosus
31. Oxidized LDL but not LDL aggravates the manifestations of experimental antiphospholipid syndrome
32. The atherogenic effect of lupus sera: Systemic lupus erythematosus derived immune complexes stimulate the accumulation of cholesterol in cultured smooth muscle cells from human aorta
33. Anti-phospholipid antibodies are directed against epitopes of oxidized phospholipids. Recognition of cardiolipin by monoclonal antibodies to epitopes of oxidized low density lipoprotein
34. Autoantibodies against oxidized LDL in antiphospholipid syndrome
35. Elevated plasma lipoprotein (a) level and its association with impaired fibrinolysis in patients with antiphospholipid syndrome
36. Thrombosis and apoptosis
37. Antiphospholipid antibody syndrome
38. Emerging cross-regulatory roles of immunity and autoimmunity in atherosclerosis
39. The mosaic of auto-immunity
40. T lymphocytes from human atherosclerotic plaques recognize oxidized low density lipoprotein
41. Induction of T cell activation by oxidized low density lipoprotein
42. Rabbit and human atherosclerotic plaques contain IgG that recognized epitopes of oxidized low density lipoprotein
43. Lipoprotein glycation and its metabolic consequences
44. Histocompatibility genes in antiphospholipid antibody syndrome
45. The immunogenetics of the antiphos-pholipid syndrome, anticardiolipin antibodies, and lupus anticoagulant
46. Anti-βGPI antibodies: Detection and association with thrombosis
47. Association of anti-βGPI antibodies with lupus-type circulating anticoagulant and thrombosis in systemic lupus erythematosus
48. Valvular dysfunction in antiphospholipid syndrome: Prevalence, clinical features, and treatment